The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
In this commentary for Barron's, KFF's Cynthia Cox and Jennifer Kates explore what will happen with costs to COVID-19 vaccines for people with and without insurance once the relevant public health emergency ends on May 11.
This survey finds that nearly four-in-ten adults say their households were recently sick with COVID-19, the Flu, or RSV, and news of the viruses is making many more likely to wear masks and take other precautions. It also explores uptake of the new bivalent booster, why many vaccinated adults have not gotten it, and enthusiasm for another shot among those who have.
Booster update remains modest; half of those already boosted are waiting for updated CDC guidelines to get another dose Nearly four in ten (38%) people say their households were affected by this winter's triple threat of viruses, with someone getting sick with the flu, COVID-19, or respiratory syncytial virus (RSV), and nearly half (46%) say…
On Tuesday, November 15, two experts joined series moderator Larry Levitt in a 45-minute discussion looking at what’s ahead for health policy on the Hill, in the Administration, and in the states after the election.
This analysis examines monkeypox (MPX) cases and vaccinations by race/ethnicity based on national data obtained from the Centers for Disease Control and Prevention (CDC). We find that while the current MPX outbreak in U.S. appears to be slowing down, disparities persist among Black and Hispanic people.
Rates of self-reported long COVID are one-quarter to one-third higher among adults who are female, transgender, Hispanic, and without a high-school degree than among all adults, according to federal survey data. In this policy watch, we consider whether long COVID could exacerbate existing disparities in health and employment.
According to a new KFF analysis assessing monkeypox (MPX) vaccine eligibility across the United States, people who are exposed or presumed exposed to MPX are generally eligible to get a vaccine across the country. However, eligibility varies across the United States for certain workers, including laboratory staff and others who might be at increased risk.
This analysis examines jurisdictional approaches to eligibility for monkeypox (MPX) vaccine. Overall, almost all jurisdictions have, at minimum, adopted the current approach laid out by the CDC. However, there is substantial variation in how eligibility is defined. Additionally, several jurisdictions lack clear criteria or information on who is eligible or where to get vaccinated. This may impact on who gets vaccinated, lead to geographic disparities, and raises potentially equity challenges.
Long COVID has been described as our “next national health disaster” and the “pandemic after the pandemic,” but we know little about how many people are affected, how long it will last for those affected, and how it could change employment and health coverage landscapes. This policy watch reviews what we know and outlines key questions to watch for regarding employment and coverage outcomes. We continue to follow the research on who is most at risk of long COVID and whether there are interventions that can reduce its incidence, length, or severity.
This analysis examines monkeypox vaccine allocations and jurisdictional requests. It explores jurisdictional request rate (the number of vaccine does requested as a share of the jurisdiction’s allocation from HHS) for JYNNEOS, the preferred vaccine. Overall, while most jurisdictions have requested at least their full supply, some are well below that mark, raising questions about how quickly their at-risk populations can get protected.
© 2025 KFF